We have located links that may give you full text access.
Oncogenic miR-155 down-regulated upon activation of antitumor cytotoxic T lymphocytes by the fusion of dendritic cells with breast carcinoma cells.
OBJECTIVE: MicroRNAs has been proved to play vital roles in many biological processes. In the present study, the expression profile of oncogenic miR-155 in the activated antitumor cytotoxic T lymphocytes generated by the fusion of dendritic cells with breast carcinoma cells has been demonstrated.
MATERIALS AND METHODS: Expression profile of oncogenic miR-155 was noted in antitumor cytotoxic T lymphocytes, which was generated by the fusion of dendritic cells (DC) with breast carcinoma cells (MCF-7). The fused cells were used to induce and generate antitumor CTL with the standard procedure. Flow cytometry, as well as qPCR analysis, were performed to identify the expression profile of oncogenic miR-155 in the generated antitumor CTL against breast cancer.
RESULTS: Compared with controls, the presence of MUC-1 and MHC-II in the DC/MCF-7 fused cells was confirmed by flow cytometry analysis. qPCR experimental results conclude that oncogenic miR-155 level was decreased in the antitumor CTL generated against breast cancer cells.
CONCLUSIONS: We observed that the oncogenic miR-155 level was down-regulated in the antitumor CTL against breast cancer, and it may be used as the effective treatment to eliminate the malignant cells in the breast cancer patients.
MATERIALS AND METHODS: Expression profile of oncogenic miR-155 was noted in antitumor cytotoxic T lymphocytes, which was generated by the fusion of dendritic cells (DC) with breast carcinoma cells (MCF-7). The fused cells were used to induce and generate antitumor CTL with the standard procedure. Flow cytometry, as well as qPCR analysis, were performed to identify the expression profile of oncogenic miR-155 in the generated antitumor CTL against breast cancer.
RESULTS: Compared with controls, the presence of MUC-1 and MHC-II in the DC/MCF-7 fused cells was confirmed by flow cytometry analysis. qPCR experimental results conclude that oncogenic miR-155 level was decreased in the antitumor CTL generated against breast cancer cells.
CONCLUSIONS: We observed that the oncogenic miR-155 level was down-regulated in the antitumor CTL against breast cancer, and it may be used as the effective treatment to eliminate the malignant cells in the breast cancer patients.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app